{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"KPS scale: 100 is no evidence of disease; 90 is able to carry on normal activity, minor symptoms of disease; 80 is normal activity with effort, some symptoms of disease; 70 is cares for self; unable to do active work; 60 is requires occasional assistance, but is able to care for most of his needs; 50 is requires considerable assistance with frequent medical care; 40 is disabled, requires special care; 30 is severely disabled, hospitalization is indicated although death is not imminent; 20 is very sick, hospitalization necessary, active support treatment necessary; 10 is moribund, fatal processes progressing rapidly, 0 is dead.","groups":[{"description":"Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG000","title":"MEDI3617 SINGLE AGENT TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG001","title":"MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG002","title":"MEDI3617 + BEVACIZUMAB Q2W TOTAL"},{"description":"Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG003","title":"MEDI3617 + PACLITAXEL TOTAL"},{"description":"Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG004","title":"MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received treatment with MEDI3617","reportingStatus":"POSTED","timeFrame":"From start of study drug administration up to 30 days after the last dose of MEDI3617","title":"Number of Participants With a Decline in Karnofsky Performance Status (KPS) of ≥ 20 Points at Worst Record On-study Compared With Baseline","type":"PRIMARY","unitOfMeasure":"Participants"}